HOME >> BIOLOGY >> NEWS
The area where carcinogens settle may be a key factor in developing lung cancer

(June 10, 2003) Bethesda, MD Environmental particles the size of those emanating from cigarette smoke and toxic aerosols interact with our pulmonary surfaces and may lead to lung disease. The location of such cancerous lesions in the bronchial airway may not be a random process, however. Instead, they may be related to a regional pattern of toxic material deposited in selected areas of the lungs. A new study suggests that a specific site the ridge separating the two halves of the bronchial airway -- may be a key factor in developing lung cancer.

Background

Earlier studies of cell dynamics indicate that benign and cancerous lesions alike predominate at the division between the central airways. One study has assessed the likelihood of finding cancer based on the site within the bronchi as ten percent for the main surface and 30 percent each for the lobar, segmental and subsegmental regions. Later research suggests that the accumulation of carcinogenic particles and particles with absorbed carcinogens from cigarette smoke at the airway's carinas -- the ridge separating the openings of the right and left main bronchi at their junction with the trachea -- is a potentially important mechanism for human pulmonary carcinogenesis. Animal studies indicate that clearing particles is much slower in the airway carinas than in the tubular airway segments.

The methods currently used to calculate exposure to particles do not take into consideration the inhomogeneity of either the deposition of the toxin or the clearance patterns of the site. The reported locations of cancer manifestation are therefore at odds with the calculated dose patterns among human bronchial airways. Accordingly, the enhanced deposition along the carinal ridges has been thought to be a more relevant deposition quantity for assessing risk than is the method of using average deposition patterns. In addition to there being increased deposits in the carcina, the streamline cu
'"/>

Contact: Donna Krupa
djkrupa1@aol.com
703-527-7357
American Physiological Society
17-Jun-2003


Page: 1 2 3 4

Related biology news :

1. New map predicts where wolves will attack
2. Scientists discover where snakes lived when they evolved into limbless creatures
3. Scientists find new way to assess where cotton-killing pests develop
4. Study finds wind, currents play key role where young fish settle
5. Study: living near where pesticides used may boost fetal death due to birth defects
6. Life in the inferno: researchers identify factors that determine where microorganisms can survive in the hellish world deep underground
7. Jefferson researchers find access to new methods of HIV prevention for pregnant women and newborns may depend on where they were receiving care
8. Bugscope Gives Internet Users Anywhere Chance To Study Insects
9. New research supports the link between cooking and carcinogens
10. Advisory panel on federal report on carcinogens makes recommendations to NIEHS/NTP for new listings
11. Suggested changes in federal report on carcinogens to be aired Oct. 21 and 22 at public meeting

Post Your Comments:
(Date:5/21/2013)... , May 21, 2013 Royal Philips Electronics ... the world,s first portable ultrasound with Philips, industry leading ... capability. The CX50 xMATRIX with available Live 3D TEE ... at the EuroPCR, official meeting for the ... Since its launch in 2012, Philips CX50 ...
(Date:5/21/2013)... modifications, which alter the way genes function without ... detected in the blood of pregnant women during ... foretell depression in the weeks after giving birth, ... debilitating. , The findings of the small study ... the journal Molecular Psychiatry . , "Postpartum ...
(Date:5/20/2013)... to the antibiotic colistin are also commonly resistant ... according to a study in mBio , ... for Microbiology. Cross-resistance to colistin and host antimicrobials ... against bacterial attack, could mean that patients with ... a crippled immune response. Colistin is a last-line ...
Breaking Biology News(10 mins):Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
(Date:5/21/2013)... Toronto, Canada (PRWEB) May 21, 2013 ... there is a strong push within the industry ... Development and Manufacturing Organizations and pharma companies often ... time frames. , Microtablets, developed in collaboration with ... how effective outsourcing can bring products to market ...
(Date:5/21/2013)... May 21, 2013 Many have long ... contributor to acne. Recently physicians from Clinical Psychiatry.com ... stress on the skin, and suggested using hypnotherapy ... the chemicals produced from stress that cause acne. , ... negative feelings acne brings about, stress causes changes in ...
(Date:5/21/2013)... Emerson Resources Inc. , a premier pharmaceutical ... Company’s Chief Executive Officer and Chairman of the Board, ... service. As part of Emerson Resources’ planned leadership succession ... as Dr. Signorino’s successor. , Dr. Signorino is ... a significant contribution to the field during his extensive ...
(Date:5/21/2013)... 21, 2013  MacroGenics, Inc. today announced that ... (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), in ... oncoprotein," will be presented at the 2013 Annual ... during the Developmental Therapeutics - Immunotherapy Oral Abstract ... 4:30 PM.  The presentation will describe the results ...
Breaking Biology Technology:The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2Adult Acne Treatment, Probiotic Action Explains How Hypnotherapy and Probiotics May Cure Various Skin Conditions 2Emerson Resources Announces CEO Retirement and Appointment of Successor 2Emerson Resources Announces CEO Retirement and Appointment of Successor 3MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
Cached News: